Autopsy report · NCT05555251

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

“After the completion of phase IA, for business reasons it was decided to terminate the study.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 1 year 6 months before it stopped.
• 18 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

BioInvent International AB

Sponsor type

Industry

Conditions

HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Metastatic Breast Cancer; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Gastric Adenocarcinoma

Interventions

BI-1607; BI-1607; Trastuzumab

Participants

18

Sites

6

Countries

Germany, Spain, United Kingdom

Trials that died the same way

• Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses
  “Study was terminated due to a business decision to cancel the entire project.” (79% match in meaning)
• Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
  “The study was terminated due to a business decision.” (79% match in meaning)
• Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
  “Study was terminated early for strategic reasons. Only Part I of the study was completed.” (78% match in meaning)
• Randomized Controlled Study to Incentivize Doctors for Appropriate Use of Medical Care in NL
  “The study was terminated due to logistical reasons” (78% match in meaning)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
  “The study was terminated due to strategic business reasons.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.